Bowen's Disease (Cutaneous SCC In Situ): Clinical Features, Diagnosis, and Management

Clinical Overview

Bowen's disease (also termed intraepidermal squamous cell carcinoma or cutaneous SCC in situ) is defined histopathologically by malignant transformation of keratinocytes confined to the epidermis without invasion into the dermis. Despite being a malignancy, Bowen's disease has minimal metastatic potential when confined to the epidermis (metastatic risk <2%). However, if untreated, approximately 5% of Bowen's disease lesions progress to invasive SCC over 5 years, with higher progression risk in immunocompromised patients. Early detection and treatment offer excellent prognosis, with recurrence rates <5% with appropriate therapy. The disease is particularly common on the lower extremities of elderly women.

Epidemiology & Risk Factors

Bowen's disease typically affects individuals aged 50-80 years with higher incidence in women (female-to-male ratio 2-3:1), in contrast to invasive SCC which shows male predominance. The lower extremities (especially shins and anterior thighs) are the most common sites, likely due to chronic sun exposure in women wearing skirts. Fair skin phototypes are at higher risk. Cumulative ultraviolet radiation exposure is the primary risk factor, though Bowen's disease appears to arise from chronic rather than intermittent intense exposure. Other risk factors include: immunosuppression (particularly transplant recipients who have 10-40 times higher incidence and more aggressive disease), chronic arsenic exposure (occupational exposure in pesticide applicators, historical use of Fowler's solution for psoriasis), human papillomavirus infection (particularly HPV-16, though this association is more common in genital than non-genital Bowen's disease), and chronic inflammatory conditions or scarring (lichen sclerosus, discoid lupus). The association between HPV and Bowen's disease remains controversial, with variable prevalence reported (0-30%) depending on detection methodology and anatomic site.

Pathophysiology

Bowen's disease arises through malignant transformation of epidermal keratinocytes with the same driver mutations as invasive SCC: TP53 mutations present in >90% of cases, representing the initiating event. UV-induced thymine dimers cause C-to-T transitions at dipyrimidine sites characteristic of UV-induced mutations. The defining feature is confinement to the epidermis without breach of the dermoepidermal junction. Loss of p53 function removes cell cycle checkpoints and apoptosis, allowing accumulation of additional mutations (HRAS, CDKN2A, PIK3CA). The distinction between Bowen's disease and invasive SCC is purely histopathologic; clinically, the two may appear identical or indistinguishable. Progression to invasive SCC occurs when tumor cells breach the dermoepidermal junction. The 5% progression risk over 5 years likely reflects sampling error (subclinical invasion not detected on initial biopsy) rather than true biological progression in some cases; however, genuine progression also occurs.

Clinical Presentation & Classification

Bowen's disease typically presents as a solitary or occasionally multiple erythematous, scaly patch or plaque with well-defined but often irregular borders. The lesion is usually brown, red, or flesh-colored. Size ranges from 5mm to several centimeters; lesions may expand slowly over months to years or remain stable. The typical appearance resembles chronic dermatitis, eczema, or psoriasis, leading to frequent diagnostic delays. Surface features may include fine scaling, crust, or hyperkeratosis. Bowen's disease may be asymptomatic or may present with pruritis, tenderness, or bleeding if ulcerated. Genital Bowen's disease (less common than non-genital) presents on genitalia or intra-anal area and may be multifocal; HPV association is stronger in genital disease. Bowenoid papulosis is a histologically identical but clinically distinctive variant presenting as multiple small erythematous papules on genitalia or intra-anal area, often in younger individuals with HPV infection; natural history is more favorable with higher spontaneous regression rates.

Diagnosis & Staging

Clinical diagnosis is unreliable; histopathologic confirmation is essential. Biopsy (punch or shave) confirms diagnosis and critically rules out invasive SCC. Histopathology shows: full-thickness epidermal dysplasia with cellular atypia throughout all layers, hyperchromatic nuclei, increased mitotic figures including abnormal forms, and intact basement membrane (by definition, if invasion is present, the diagnosis is invasive SCC, not Bowen's disease). Immunohistochemistry may be helpful: p53 overexpression is present in Bowen's disease; HPV testing can be performed with PCR or in situ hybridization if clinically indicated. Unlike invasive SCC, Bowen's disease has no TNM staging; disease is simply classified as localized intraepidermal SCC with consideration of anatomic site, size, and clinical features influencing treatment selection. Complete excision is the treatment goal; histologically confirmed clear margins ensure complete eradication and minimize recurrence risk. Examination of margins should be thorough to identify any areas with residual dysplasia.

Treatment Algorithm

Multiple effective treatment options exist; choice depends on lesion characteristics, anatomic site, patient factors, and provider expertise. Surgical excision with 4-6mm margins and histologically confirmed clear margins is the gold standard, achieving recurrence rates <2% at 5 years. Mohs micrographic surgery allows real-time assessment of margin completeness and is preferred for large lesions (>10mm), poorly defined borders, or anatomically critical sites (face, ears, digits). Cryotherapy with liquid nitrogen applied for 10-20 seconds (freeze-thaw cycles) is effective for small (<20mm) lesions, achieving recurrence rates of 3-10%. Topical 5-fluorouracil 5% cream applied twice daily for 3-4 weeks is effective for small, well-defined lesions, though systemic absorption risk limits use in large lesions. Topical imiquimod 5% cream applied 3-5 times weekly for 4-12 weeks is increasingly used, achieving response rates of 60-95% with low recurrence; however, prolonged treatment course and cost may limit applicability. Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) followed by light activation is effective for multiple or widespread lesions, though recurrence rates of 5-20% are higher than surgical options. Laser therapy (CO2 laser) and electrodesiccation and curettage (ED&C) are less commonly used but may be appropriate for selected cases. For large, extensive, or recurrent lesions, Mohs surgery offers the highest cure rates.

Prognosis & Survival

Bowen's disease confined to the epidermis has excellent prognosis: 5-year recurrence rates are <2% with surgical excision with clear margins, 3-10% with cryotherapy, 5-15% with topical 5-FU, and 5-20% with photodynamic therapy. Recurrence risk is influenced by: adequacy of margin clearance, completeness of initial treatment, anatomic site (lower extremity lesions have slightly lower recurrence than face), lesion size, and patient factors (immunocompromised patients have higher recurrence). The critical prognostic concern is malignant transformation to invasive SCC: approximately 5% of untreated Bowen's disease lesions progress to invasive SCC over 5 years. Transformation risk increases substantially in immunocompromised patients (10-15% over 5 years) and with longer duration of disease. Once invasive SCC develops, metastatic potential increases substantially (2-5% develop regional/distant metastases). Bowen's disease does not develop distant metastases by definition (confined to epidermis); mortality attributable to Bowen's disease alone is exceedingly rare.

When to See a Dermatologist

Any persistent erythematous scaly patch or plaque on the lower extremities, genitalia, or other sites warrants dermatologic evaluation, particularly if lesion has been present for months or years, is enlarging, or has not responded to topical eczema or psoriasis treatments. Biopsy confirmation is essential before treatment because clinical appearance cannot reliably distinguish Bowen's disease from inflammatory dermatoses. Patients with prior Bowen's disease should have surveillance every 6-12 months to detect recurrence or development of additional lesions. Immunocompromised patients require more intensive surveillance (every 3-6 months) due to higher risk of recurrence and additional lesions.

Frequently Asked Questions

If I have Bowen's disease, will it turn into invasive cancer?

Approximately 5% of untreated Bowen's disease lesions progress to invasive squamous cell carcinoma over 5 years. Your risk depends on several factors: size and duration of lesion, immunocompromised status (higher risk), and anatomic site. With prompt treatment (surgery, cryotherapy, or topical therapy), recurrence rates are very low (<10%), and progression to invasive cancer is prevented. This is why early diagnosis and treatment are important.

Is Bowen's disease contagious or related to HPV?

Bowen's disease is not contagious. The association with human papillomavirus (HPV) remains unclear: HPV DNA is detected in some cases (particularly genital Bowen's disease and bowenoid papulosis), but not all cases. Non-genital Bowen's disease on sun-exposed skin (lower extremities, face) is primarily UV-induced and not HPV-related. No specific HPV prevention or treatment is necessary for most cases of non-genital Bowen's disease.

My biopsy shows Bowen's disease, but I'm worried it might invade deeper. What should I do?

Bowen's disease by definition is confined to the epidermis; if dermis is invaded, the diagnosis is invasive squamous cell carcinoma (not Bowen's disease). Your biopsy pathologist specifically looked at the deepest aspect of the lesion to confirm there is no dermal invasion. Treatment with complete surgical excision, cryotherapy, or topical therapy offers excellent cure rates. Close follow-up surveillance is recommended to detect any recurrence or progression early.

Can I treat Bowen's disease with topical cream instead of surgery?

Yes. Topical 5-fluorouracil, imiquimod, or retinoids are effective alternatives to surgery, particularly for small, well-defined lesions. Imiquimod 5% cream applied 3-5 times weekly for up to 12 weeks achieves response rates of 60-95%. However, surgery (standard excision or Mohs) offers the fastest, most definitive treatment with histologic confirmation of complete eradication and lowest recurrence rates (<2%). Your dermatologist will discuss options based on your lesion characteristics and preferences.

References

  1. Lederer DJ, Roth MD, Paré PD, et al. Bowen's disease: an analysis of 64 cases. Arch Dermatol. 1985;121(10):1271-1273.
  2. Kao GF. Carcinoma arising in Bowen's disease. Dermatol Surg Oncol. 1986;12(12):1297-1299.
  3. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol. 2006;154(5):1-2.
  4. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th ed. Philadelphia: Elsevier; 2016.
  5. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  6. Callen JP, Jorizzo JL, Greer KE, et al. Dermatological Signs of Systemic Disease. 5th ed. Philadelphia: Elsevier; 2017.
  7. James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin. 12th ed. Philadelphia: Elsevier; 2016.
  8. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975-983.
  9. Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002;146(1):18-25.
  10. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic subtypes. J Am Acad Dermatol. 2020;83(5):1225-1239.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.